NCT05672927View on ClinicalTrials.gov

Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

PHASE4RecruitingINTERVENTIONAL
Enrollment

618

Participants

Timeline

Start Date

January 18, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions
ImmunizationHPV InfectionHuman Papillomavirus
Interventions
BIOLOGICAL

9-valent HPV vaccine, 2 doses alternate timing

Evaluate 2 doses of the 9-valent HPV vaccine across a 12-month period following the 1st dose among 27-45-year-old females.

BIOLOGICAL

9-valent HPV vaccine, 3 doses standard timing

This will be the comparison group for the 2-dose group.

Trial Locations (1)

77555

RECRUITING

University of Texas Medical Branch, Galveston

All Listed Sponsors
collaborator

Cancer Prevention Research Institute of Texas

OTHER

lead

The University of Texas Medical Branch, Galveston

OTHER